| olanzapine / Generic mfg. |
NCT00007774: To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia |
|
|
| Completed | 4 | 600 | US | Haloperidol, Olanzapine | US Department of Veterans Affairs, Eli Lilly and Company | Schizoaffective Disorder, Schizophrenia | 06/01 | | | |
NCT00378183: A Study Comparing Three Strategies to Switch Patients With Schizophrenia or Schizoaffective Disorder to Risperidone After Unsuccessful Treatment With Olanzapine. |
|
|
| Completed | 4 | 120 | US | risperidone | Janssen, LP | Schizoaffective Disorder, Schizophrenia | | 05/02 | | |
NCT00169065: Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia |
|
|
| Completed | 4 | 38 | US | Clozapine, Olanzapine | Harvard Medical School (HMS and HSDM), National Institute of Mental Health (NIMH), Dartmouth-Hitchcock Medical Center, Commonwealth Research Center, Massachusetts, Eli Lilly and Company | Schizophrenia | 06/02 | 06/02 | | |
NCT00036088: Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia |
|
|
| Completed | 4 | 530 | US, Europe, RoW | Olanzapine | Eli Lilly and Company | Schizophrenia | | 07/02 | | |
NCT00034580: Olanzapine Versus Active Comparator in the Treatment of Bipolar I Disorder |
|
|
| Completed | 4 | 326 | US | olanzapine, risperidone | Eli Lilly and Company | Bipolar Disorder | | 08/02 | | |
NCT00034801: Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia |
|
|
| Completed | 4 | 378 | US | olanzapine, ziprasidone | Eli Lilly and Company | Depression, Schizophrenia, Schizoaffective Disorder | | 03/03 | | |
NCT00044187: The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder |
|
|
| Completed | 4 | 130 | US | Sibutramine | Eli Lilly and Company | Schizophrenia, Psychotic Disorders, Bipolar Disorder | | 09/03 | | |
NCT00485823: Assessment of a Weight Management Program for Weight Gain in Patients With Schizophrenia |
|
|
| Completed | 4 | 48 | RoW | Olanzapine Hydrochloride, Weight Management Program | Eli Lilly and Company | Schizophrenic Disorders | | 09/03 | | |
NCT00486005: Weight Gain Management in Patients With Schizophrenia |
|
|
| Completed | 4 | 74 | RoW | Olanzapine Hydrochloride, Nizatidine, Placebo | Eli Lilly and Company | Schizophrenia | | 10/03 | | |
NCT00485498: Managing Acute Schizophrenia, a Comparison Between Two Atypical Antipsychotics |
|
|
| Completed | 4 | 122 | RoW | Olanzapine Hydrochloride, Risperidone | Eli Lilly and Company | Schizophrenia | | 12/03 | | |
NCT00592930: Olanzapine in the Treatment of Anorexia Nervosa |
|
|
| Completed | 4 | 20 | US | olanzapine, placebo | Northwell Health, Eli Lilly and Company | Anorexia Nervosa | 12/04 | 12/04 | | |
| Terminated | 4 | 11 | Europe | olanzapine, LY170053, Zyprexa, haloperidol, zuclopentixol | Eli Lilly and Company | Bipolar Disorder | 04/05 | 04/05 | | |
NCT00050206: Olanzapine Versus Placebo in the Treatment of Mania in Adolescents With Bipolar I Disorder |
|
|
| Completed | 4 | 130 | US | Olanzapine, Placebo | Eli Lilly and Company | Bipolar Disorder | | 05/05 | | |
NCT00191828: A Study on Induced Weight Gain During Atypical Antipsychotic Treatment and Its Management With Psychoeducational Programme |
|
|
| Completed | 4 | 60 | Europe | olanzapine | Eli Lilly and Company | Weight Gain | | 08/05 | | |
NCT00100776: Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder |
|
|
| Completed | 4 | 600 | US | Olanzapine | Eli Lilly and Company | Schizophrenia, Schizoaffective Disorder | | 11/05 | | |
NCT00182507: Olanzapine in the Treatment of Hair Pulling (Trichotillomania) |
|
|
| Completed | 4 | 34 | Canada | Olanzapine | Hamilton Health Sciences Corporation, Eli Lilly and Company | Trichotillomania | | 03/06 | | |
NCT00108368: The Effects of Risperidone and Olanzapine on Thinking |
|
|
| Completed | 4 | | US | Risperidone, Olanzapine | US Department of Veterans Affairs, Janssen, LP | Schizophrenia, Psychotic Disorders | | 03/06 | | |
| Completed | 4 | 80 | Canada | Olanzapine & Quetiapine | Hamilton Health Sciences Corporation, AstraZeneca | Schizophrenia | | 03/06 | | |
NCT00090012: Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder |
|
|
| Completed | 4 | 340 | US | Olanzapine, Quetiapine | Eli Lilly and Company | Schizophrenia, Schizoaffective Disorder | | 03/06 | | |
| Completed | 4 | 180 | Europe | Olanzapine | Eli Lilly and Company | Bipolar Disorder | | 03/06 | | |
NCT00191555: Efficacy Study of Switching Stabilized Schizophrenic Patients From Conventional to Atypical Antipsychotic Treatment |
|
|
| Completed | 4 | 360 | Europe | olanzapine, haloperidol | Eli Lilly and Company | Schizophrenia | | 05/06 | | |
| Completed | 4 | 120 | Europe, RoW | olanzapine, carbamazepine | Eli Lilly and Company | Bipolar Disorder | | 06/06 | | |
NCT00103571: Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia |
|
|
| Completed | 4 | 600 | US | Olanzapine, Aripiprazole | Eli Lilly and Company | Schizophrenia | | 08/06 | | |
NCT00071253: Depakote Monotherapy, Olanzapine Monotherapy, and Combination Therapy of Depakote Plus Olanzapine in Stable Subjects During the Maintenance Phase of Bipolar Illness |
|
|
| Terminated | 4 | 180 | US | Divalproex Sodium (Delayed-Release Tablets), Divalproex Sodium (Extended-Release Tablets), Olanzapine | Abbott | Bipolar Disorder | | | | |
NCT00094549: Olanzapine vs. Comparator and Placebo in the Treatment of Patients With Bipolar I Disorder |
|
|
| Completed | 4 | 500 | US, Europe, RoW | olanzapine, divalproex sodium, placebo | Eli Lilly and Company | Bipolar Disorder | | 12/06 | | |
| Completed | 4 | 24 | US | Ziprasidone | North Suffolk Mental Health Association, Pfizer | Schizophrenia | | 03/07 | | |
NCT00418171: Large Simple Trial (LST) Of Cardiovascular Safety Of Ziprasidone And Olanzapine- (Zodiac) |
|
|
| Completed | 4 | 18239 | US | Ziprasidone, Olanzapine | Pfizer | Schizophrenia | | 04/07 | | |
NCT00208819: A Comparison of Two Standard Therapies in the Management of Dementia With Agitation |
|
|
| Completed | 4 | 50 | US | risperidone, quetiapine, olanzapine, divalproex | Emory University, Abbott | Senile Dementia, Alzheimer Type, Dementia, Alzheimer Type, Alzheimer Disease, Dementia | | 07/07 | | |
NCT00088049: Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia |
|
|
| Completed | 4 | 560 | US | Olanzapine, Aripiprazole | Eli Lilly and Company | Schizophrenia | | 07/07 | | |
NCT00351936: A Placebo-Controlled, Cross-Over Trial of Aripiprazole |
|
|
| Completed | 4 | 16 | US | Aripiprazole, placebo | North Suffolk Mental Health Association, Eli Lilly and Company | Schizophrenia | 07/07 | 07/07 | | |
NCT00231335: Efficacy and Safety Study of Escitalopram Augmentation in Treatment Resistant Schizophrenia |
|
|
| Completed | 4 | 30 | US | escitalopram | Emory University, Forest Laboratories | Schizophrenia, Schizoaffective Disorder | | 07/07 | | |
NCT00419653: Modulation of Regional Brain Activation in Schizophrenic Patients by Pharmacological Therapy |
|
|
| Terminated | 4 | 19 | Europe | Amisulpride, Olanzapine, Haloperidol | University of Jena, Sanofi | Schizophrenia | 09/07 | 09/07 | | |
NCT00287820: Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism |
|
|
| Completed | 4 | 46 | US | Olanzapine, ayprexa, olanzapine, zyprexa, risperidone, riperidal | Nathan Kline Institute for Psychiatric Research, Eli Lilly and Company | Schizophrenia, Diabetes, Metabolic Syndrome, Hyperglycemia | | 09/07 | | |
PREFERENCE, NCT00324051: Patient's Preference Between Conventional Oral Olanzapine Tablet vs Olanzapine Orodispersible Tablet |
|
|
| Completed | 4 | 284 | Europe, RoW | olanzapine therapy | Eli Lilly and Company | Schizophrenia | 09/07 | 09/07 | | |
PLATYPUS, NCT00303602: Comparing the Effect of Under the Tongue Olanzapine Versus Swallowed Olanzapine on Body Mass Index (A Ratio of Weight to Height) |
|
|
| Completed | 4 | 149 | US, Canada, Europe, RoW | Sublingual orally disintegrating olanzapine (SODO), LY170053, Zydis, Oral olanzapine, Zyprexa | Eli Lilly and Company | Schizophrenia, Schizoaffective Disorder, Bipolar Disorder | 12/07 | 12/07 | | |
NCT00337662: Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia |
|
|
| Completed | 4 | 628 | US, RoW | olanzapine, LY170053, Zyprexa, risperidone | Eli Lilly and Company | Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder | 12/07 | 12/07 | | |
NCT00402324: A Comparison of Olanzapine in Combination With a Mood Stabilizer vs Mood Stabilizer Alone, in Mixed Bipolar Patients |
|
|
| Completed | 4 | 202 | US | olanzapine, LY170053, Zyprexa, placebo, divalproex | Eli Lilly and Company | Bipolar I Disorder | 02/08 | 02/08 | | |
NCT00176436: Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients |
|
|
| Completed | 4 | 40 | US | Diet support group, Group counseling and exercise | University of Maryland, Baltimore, Eli Lilly and Company | Schizophrenia | 03/08 | 03/08 | | |
NCT00190749: Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder |
|
|
| Completed | 4 | 130 | US | olanzapine, LY170053, Zyprexa, risperidone | Eli Lilly and Company | Schizophrenia, Schizoaffective Disorder | 06/08 | 06/08 | | |
NCT00290121: Appetite Increase in Schizophrenia Patients Treated With Atypical Antipsychotics |
|
|
| Completed | 4 | 25 | Canada | Olanzapine | Université de Montréal, Centre de Recherche de l'Institut Universitaire en santé Mentale de Montréal, Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal, Hopital du Sacre-Coeur de Montreal, Eli Lilly and Company | Schizophrenia | 06/08 | 06/08 | | |
NCT00246259: A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early Psychosis |
|
|
| Completed | 4 | 77 | Canada | Risperidone long-acting injection (LAI), Oral Antipsychotic | Janssen-Ortho Inc., Canada | Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorders | 12/08 | 12/08 | | |
NCT00508157 / 2007-001217-42: A Phase 4 Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome |
|
|
| Terminated | 4 | 125 | Europe, RoW | Aripiprazole, Abilify, BMS-337039, Continued Antipsychotic (Risperidone or Quetiapine or Olanzapine) | Bristol-Myers Squibb, Otsuka America Pharmaceutical | Metabolic Syndrome, Schizophrenia | 03/09 | 03/09 | | |
NCT00520507: An Investigation of the Sleep Architecture and Consequent Cognitive Changes in Olanzapine-Treated Depressed Patients |
|
|
| Completed | 4 | 27 | Canada | Olanzapine, Placebo | Queen's University, Eli Lilly and Company | Bipolar Disorder, Depression, Depressive Disorder | 05/09 | 05/09 | | |
NCT00394095: Topiramate vs. Placebo in Preventing Weight Gain in Bipolar Disorder Treated With Olanzapine |
|
|
| Completed | 4 | 31 | US | Topiramate, Topamax, Placebo, Sugar pill | University of Cincinnati, Eli Lilly and Company | Bipolar Disorder, Weight Gain | 08/09 | 09/09 | | |
NCT00338949: Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes |
|
|
| Completed | 4 | 77 | US | Switch, ziprasidone, Control, risperidone, olanzapine | Veterans Medical Research Foundation, National Institute of Mental Health (NIMH), Pfizer | Schizophrenia, Metabolic Syndrome X, Insulin Resistance | 12/09 | 12/09 | | |
| Completed | 4 | 20 | US | orally-disintegrating olanzapine, Zydis, regular olanzapine, Zyprexa | Vanderbilt University, Eli Lilly and Company | Bipolar Depression | 03/10 | 03/10 | | |
| Completed | 4 | 50 | US | Olanzapine/Zyprexa, Zyprexa | Stanford University, Eli Lilly and Company | Bipolar Disorder | 06/10 | 06/10 | | |
NCT00690235: Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia |
|
|
| Completed | 4 | 33 | US | Pramlintide, Amylin, Placebo, sterile saline | University of Texas Southwestern Medical Center, Amylin Pharmaceuticals, LLC. | Schizophrenia, Schizoaffective Disorder, Diabetes, Weight Gain | 08/11 | 08/11 | | |
| Completed | 4 | 501 | US | iloperidone, Fanapt™ | Novartis | Schizophrenia | 01/12 | 01/12 | | |
| Completed | 4 | 300 | Europe | Aripiprazole, ATC code: N05AX12, Olanzapine, ATC code: N05AH03, Haloperidol, ATC code: N05AD01 | Mario Negri Institute for Pharmacological Research, Bristol-Myers Squibb | Schizophrenia | 06/12 | 06/13 | | |
| Completed | 4 | 203 | US, Europe, RoW | Olanzapine, Zyprexa, LY170053, Standard behavioral weight intervention, Intense behavioral weight intervention | Eli Lilly and Company | Bipolar I Disorder, Schizophrenia | 05/13 | 05/13 | | |
NCT01592201: A Comparative Study of Patient Satisfaction Between Continued Administration of Previous Antipsychotics Versus Switched Administration to Paliperidone ER in Non-satisfied Patients With Previous Antipsychotic Drug |
|
|
| Terminated | 4 | 13 | RoW | Paliperdidone ER, Aripiprazole, olanzapine and risperidone (Antipsychotics) | Janssen Korea, Ltd., Korea | Schizophrenia | 06/13 | 06/13 | | |
NCT01920802: Assessment and Comparison of Metabolic Changes in Non-psychotic Adults Taking Iloperidone or Olanzapine or Placebo |
|
|
| Completed | 4 | 31 | US | olanzapine, Zyprexa, iloperidone, Fanapt, Placebo | New York State Psychiatric Institute, Novartis Pharmaceuticals | Healthy | 08/14 | 09/14 | | |
NCT00845507: Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults |
|
|
| Completed | 4 | 54 | US | Exenatide, Exenatide (Byeta), Placebo | University of Cincinnati, Eli Lilly and Company | Weight Gain | 07/15 | 07/15 | | |
2004-001482-17: Olanzapine Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated with Bipolar I disorder. |
|
|
| Completed | 4 | 70 | Europe | Zyprexa, Depakote, LY170053, Zyprexa (5mg) (Encapsulated), Depakote (Encapsulated), Zyprexa (5mg) (Encapsulated), Depakote (Encapsulated) | Eli Lilly and Company | Manic or Mixed Episodes Associated with Bipolar I Disorder | | 12/06 | | |
NCT02282085: Treatment Study Comparing Aripiprazole Once Monthly With Standard of Care Medication in Outpatients With Schizophrenia |
|
|
| Unknown status | 4 | 200 | US | Aripiprazole Once-Monthly, Oral Antipsychotic (i.e. aripiprazole, risperidone, lurasidone, quetiapine, olanzapine, ziprasidone, etc) | Matt Byerly, Otsuka America Pharmaceutical | Schizophrenia | 12/17 | | | |
NCT02237417: Study of the Impact of Aripiprazole (Abilify®) Once Monthly Versus Standard of Care Oral Antipsychotic Medications on Changes in Brain Structure and Metabolism |
|
|
| Completed | 4 | 47 | US | Standard of Care Oral antipsychotics, IM aripiprazole once monthly, No Treatment | Deborah Yurgelun-Todd, Otsuka America Pharmaceutical | Schizophrenia | 11/18 | 07/20 | | |
| Not yet recruiting | 4 | 60 | Europe | DM-Aripiprazole, DM-Olanzapine, DM- Quetiapine, DM-Risperidone, Tablet, Aripiprazole, Olanzapine, Quetiapine, Risperidone | Otsuka Pharmaceutical, Otsuka Pharmaceutical | Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis, Schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
NCT03568500: A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic |
|
|
| Completed | 4 | 44 | Europe | Digital Medicine System, Aripiprazole, Olanzapine, Quetiapine, Risperidone | Otsuka Pharmaceutical Development & Commercialization, Inc. | Schizophrenia, Schizoaffective Disorder, First Episode Psychosis | 05/19 | 09/19 | | |
2020-000102-28: Does the glucagon-like peptide-1 receptor agonist semaglutide prevent deterioration of metabolic state in prediabetic or diabetic patients with schizophrenia treated with the antipsychotic compounds clozapine or olanzapine? Kan tillægsbehandling med glukagonlignende peptid-1 receptoragonisten semaglutid forebygge forværring af metaboliske forstyrrelser hos prediabetiske og diabtetiske skizofrene patienter, der er i behandling med olanzapin eller clozapin? |
|
|
| Not yet recruiting | 4 | 104 | Europe | Suspension for injection in pre-filled pen, Ozempic | Mental Healt Center Copenhagen, Novo Nordisk, Region Hovedstaden Psykiatri | Schizophrenia spectrum disorder F20-F29, Mental Health Psykisk sygdom, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
NCT03571126: Olanzapine for the Prevention and Treatment of Nausea and Vomiting Induced by Chemotherapy of Lung Cancer |
|
|
| Recruiting | 4 | 156 | RoW | Olanzapine, Placebos | Zunyi Medical College, Zunyi First People's Hospital, Affiliated Hospital of North Sichuan Medical College, Sichuan Cancer Hospital and Research Institute, Guizhou Provincial People's Hospital, Affiliated Hospital of Southwest Medical University | Chemotherapy-induced Nausea and Vomiting, Lung Cancer | 10/22 | 08/23 | | |
NCT05213143: The Safety and Efficacy of Lurasidone In Subjects With Schizophrenia Switched From Olanzapine |
|
|
| Terminated | 4 | 13 | RoW | Lurasidone | Sumitomo Pharma (Suzhou) Co., Ltd. | Schizophrenia | 11/22 | 11/22 | | |
